| Literature DB >> 31696123 |
Danielle E Crosby1, Raphael Labens1, Kristopher J Hughes1, Sharon Nielsen2, Bryan J Hilbert1.
Abstract
Synovial infections (SI) are common in horses of all ages and can be associated with high rates of morbidity and mortality. Identifying factors influencing survival and return to function may be useful for management of affected individuals and determination of prognosis. The objectives of this study were to identify factors associated with survival and return to function of horses and foals with SI presented to an equine hospital. This study is a retrospective case series. Data were collected from medical records of all horses with SI that were presented to a single equine hospital between April 1st, 2008 and May 1st, 2017. Long-term follow up was obtained by a semi-structured telephone questionnaire of clinical outcomes and analysis of online race records. Univariate models were created using generalized linear and linear mixed models to assess factors associated with outcomes. Multivariable models were created using generalized linear and linear mixed models to determine factors significantly associated with outcomes. Of 186 horses presented with SI, 161/186 (86.6%) were treated and 145/161 (90.1%) survived to discharge. The majority of joints were treated with synovial lavage (93.8%). One hundred and twenty horses were included in the return to function analysis and 79 (65%) returned to function. Increasing number of days of treatment with systemic antimicrobials was associated with increased likelihood of survival for each horse (OR 1.15, 95% CI 1.04-1.27, P = 0.025) and when considering each individual synovial structure (OR 1.11, 95% CI 1.04-1.17, P = 0.004). Horses treated with doxycycline were less likely to return to function (OR 0.39, 95% CI 0.19-0.8, P = 0.031). The overall rate of survival of horses treated with SI is good. The likelihood of return to function is lower than for survival. The findings of this study, combined with relevant antimicrobial stewardship practices, can be used as a part of evidence-based decision-making when veterinarians are treating horses with SI.Entities:
Keywords: horse; joint; outcome; prognosis; synovial structure
Year: 2019 PMID: 31696123 PMCID: PMC6817570 DOI: 10.3389/fvets.2019.00367
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Figure 1Flow diagram illustrating the process to inclusion of horses and foals.
Frequency of distribution of infected synovial cavities.
| Calcaneal bursa | 8 (3.3) |
| Carpal sheath | 3 (1.3) |
| Cubital joint | 6 (2.5) |
| Digital flexor tendon sheath | 42 (17.5) |
| Distal interphalangeal joint | 17 (7.1) |
| Distal intertarsal joint | 1 (0.4) |
| Extensor carpi radialis sheath | 2 (0.8) |
| Femoropatella joint | 23 (9.6) |
| Femorotibial joint (medial or lateral) | 5 (2.1) |
| Middle carpal joint | 16 (6.7) |
| Fetlock joint | 36 (15.0) |
| Navicular bursa | 9 (3.8) |
| Proximal interphalangeal joint | 9 (3.8) |
| Proximal intertarsal joint | 1 (0.4) |
| Antebrachiocarpal joint | 13 (5.4) |
| Glenohumeral joint | 2 (0.8) |
| Tarsal sheath | 3 (1.3) |
| Tarsocrural joint | 41 (17.1) |
| Tarsometatarsal joint | 3 (1.3) |
| Total | 240 |
Survival and return to function of horses by use.
| All | 186 | 161/186 (86.6) | 145/161 (90.1) | 78/120 (65.8) |
| Thoroughbred | 47/84 (25.3) | 43/47 (91.5) | 39/43 (90.7) | 18/36 (50) |
| Standardbred | 37/84 (19.9) | 31/37 (83.8) | 25/31 (80.6) | 12/24 (50) |
| Campdrafting and western sports | 16/54 (8.6) | 12/16 (75) | 11/12 (91.7) | 7/8 (87.5) |
| Dressage | 9/54 (4.8) | 7/9 (77.8) | 6/7 (85.7) | 2/3 (66.7) |
| Endurance | 2/54 (1.1) | 2/2 (100) | 2/2 (100) | 1/1 (100) |
| Eventing | 3/54 (1.6) | 3/3 (100) | 3/3 (100) | 3/3 (100) |
| Harness | 2/54 (1.1) | 2/2 (100) | 2/2 (100) | 2/2 (100) |
| Polo & polo crosse | 13/54 (7) | 13/13 (100) | 13/13 (100) | 5/7 (71.4) |
| Rodeo | 2/54 (1.1) | 1/2 (50) | 1/1 (100) | 0/1 (0) |
| Show horses | 3/54 (1.6) | 3/3 (100) | 3/3 (100) | 1/3 (33.3) |
| Show jumping | 4/54 (2.2) | 4/4 (100) | 4/4 (100) | 4/4 (100) |
| General purpose | 11/48 (5.9) | 10/11 (90.9) | 9/10 (90) | 7/9 (77.8) |
| Broodmares | 15/48 (8.1) | 13/15 (86.7) | 13/13 (100) | 12/12 (100) |
| Breeding stallions | 2/48 (1.1) | 1/2 (50) | 1/1 (100) | 1/1 (100) |
| Paddock companions | 2/48 (1.1) | 1/2 (50) | 1/1 (100) | 1/1 (100) |
| Unknown | 18/48 (9.7) | 15/18 (83.3) | 12/15 (80) | 2/5 (40) |
The text in bold refers to the total numbers of horses grouped by differing athletic requirements.
Multivariable analysis for survival and return to function.
| Number of days (total) on systemic antimicrobials | 0.025 | 1.15 | 1.04–1.27 |
| Number of days (total) on systemic antimicrobials | 0.004 | 1.11 | 1.04–1.17 |
| Doxycycline | 0.031 | 0.39 | 0.19–0.8 |
Descriptive data on return to function for racehorses that survived to discharge.
| All | 30/60 (50) | 0 | 0–50 | 13 | 1–55 | 0 | 0–9 | 1 | 0–9 | 0 | 0–16 | 2 | 0–18 | $0 | $0–$53,594 | $7,160 | $0–$59,859 |
| TB | 18/36 (50) | 0 | 0–14 | 8.5 | 1–32 | 0 | 0–3 | 0 | 0–3 | 0 | 0–3 | 1 | 0–8 | $0 | $0–$37,990 | $3742.5 | $0–$59,110 |
| SB | 12/24 (50) | 0 | 0–50 | 33 | 7–55 | 0 | 0–9 | 2 | 0–9 | 0 | 0–16 | 6 | 0–18 | $0 | $0–$53,594 | $12,124 | $645–$59,859 |
Thoroughbred.
Standardbred.
Australian Dollars.